CTMX vs FHTX
CTMX: CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer. FHTX: Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression.
Side-by-side fundamentals
| Metric | CTMX | FHTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.33 | $5.21 | |
| Market cap as of 2026-07-23 | $724M | $306M | |
| Net margin as of 2026-07-23 | -166.4% | -266.9% | CTMX higher |
| Operating margin as of 2026-07-23 | -181.9% | -301.3% | CTMX higher |
| ROE as of 2026-07-23 | -36.6% | -301.6% | CTMX higher |
| ROA as of 2026-07-23 | -28.0% | -35.4% | CTMX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -75.9% | +20.1% | FHTX higher |
| Revenue CAGR (3y) SEC XBRL | +12.8% | +17.1% | FHTX higher |
| Beta as of 2026-07-23 | 2.16 | 2.80 | |
| 1-year return as of 2026-07-22 close | +43.7% | -15.4% | CTMX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.